GlassScriptPhysician profile
Christopher Thomas Garbowski
NPI 1154742559
$8,487.41
in general payments reported to CMS, 2019-2025
32 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $358 · 2021: $4,425 · 2022: $1,153 · 2023: $465 · 2024: $832 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $4,046.27 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $596.42 | 2019-2022 | |
| Smith+Nephew, INC. | $550.00 | 2019-2024 | Stravix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $350.88 | 2019-2025 | Jublia |
| Abbvie INC. | $328.15 | 2021-2025 | |
| Averitas Pharma INC. | $256.78 | 2023-2024 | Qutenza |
| Paratek Pharmaceuticals, INC. | $254.37 | 2021-2025 | Nuzyra |
| Misonix INC | $240.67 | 2019-2021 | |
| Stryker Corporation | $194.65 | 2019-2023 | Easyfuse |
| Kerecis Limited | $176.43 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Horizon Therapeutics Plc | $163.58 | 2020-2023 | Krystexxa |
| Abbott Laboratories | $148.91 | 2025 | Esprit |
| Globus Medical, INC. | $147.74 | 2025 | Senza |
| Medtronic, INC. | $117.33 | 2024 | Intellis Adaptivestim |
| Organogenesis INC. | $112.25 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Anika Therapeutics, INC. | $105.84 | 2022 | |
| Depuy Synthes Sales INC. | $90.14 | 2019 | |
| Bioventus LLC | $78.72 | 2019-2022 | |
| Paragon 28, INC. | $76.47 | 2022 | |
| Grt US Holding, INC. | $73.76 | 2022 | |
| Acera Surgical, INC. | $71.52 | 2022 | |
| Next Science LLC | $46.67 | 2022 | |
| Kci USA, INC. | $45.60 | 2021 | |
| Zyla Life Sciences, INC. | $38.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.89 | 2019 | |
| Sebela Pharmaceuticals INC. | $35.95 | 2019 | |
| Integra Lifesciences Corporation | $19.19 | 2022 | |
| Amgen INC. | $17.48 | 2025 | Krystexxa |
| Wright Medical Technology, INC. | $17.06 | 2020 | |
| Heron Therapeutics, INC. | $17.00 | 2022 | |
| Allergan, INC. | $15.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Garbowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.